-
公开(公告)号：US20210324096A1
公开(公告)日：2021-10-21
申请号：US17108373
申请日：2020-12-01
Applicant: GENMAB B.V.
Inventor： Marije OVERDIJK , Kristin STRUMANE , Rik RADEMAKER , Esther BREIJ , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
-
公开(公告)号：US20210238296A1
公开(公告)日：2021-08-05
申请号：US17051205
申请日：2019-05-03
Applicant: GENMAB B.V.
Inventor： Rob DE JONG , Frank BEURSKENS , Simone OOSTINDIE , Aran Frank LABRIJN , Kristin STRUMANE , Janine SCHUURMAN , Bart-Jan DE KREUK
Abstract: Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
-
公开(公告)号：US20210163619A1
公开(公告)日：2021-06-03
申请号：US16921154
申请日：2020-07-06
Applicant: GENMAB B.V.
Inventor： Paul PARREN , Frank BEURSKENS , Rob N. DE JONG , Aran Frank LABRIJN , Janine SCHUURMAN
Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
-
公开(公告)号：US20190315877A1
公开(公告)日：2019-10-17
申请号：US16451714
申请日：2019-06-25
Applicant: GENMAB B.V.
Inventor： Marije OVERDIJK , Kristin STRUMANE , Rik RADEMAKER , Esther BREIJ , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
-
公开(公告)号：US20200181277A1
公开(公告)日：2020-06-11
申请号：US16482747
申请日：2018-02-12
Applicant: GENMAB B.V.
Inventor： Frank BEURSKENS , Marije OVERDIJK , Annieck M. DIKS , Rob DE JONG , Kristin STRUMANE , Janine SCHUURMAN , Paul PARREN
Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
-
Patent Agency Ranking
公开(公告)号：US20190202926A1
公开(公告)日：2019-07-04
申请号：US15780285
申请日：2016-12-01
Applicant: GENMAB B.V.
Inventor： Frank BEURSKENS , Marije OVERDIJK , Rob DE JONG , David SATIJN , Kristin STRUMANE , Janine SCHUURMAN , Paul PARREN
CPC classification number: C07K16/2878 , A61K38/00 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/30 , C07K16/46 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/526 , C07K2317/73 , C07K2317/75 , C12N15/62
Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
-
公开(公告)号：US20220411522A1
公开(公告)日：2022-12-29
申请号：US17684238
申请日：2022-03-01
Applicant: GENMAB B.V.
Inventor： Frank BEURSKENS , Marije OVERDIJK , Rob DE JONG , David SATIJN , Kristin STRUMANE , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
-
公开(公告)号：US20150337049A1
公开(公告)日：2015-11-26
申请号：US14760157
申请日：2014-01-09
Applicant: GENMAB B.V.
Inventor： Aran Frank LABRIJN , Joyce MEESTERS , Joost J. NEIJSSEN , Edward Norbert VAN DEN BRINK , Janine SCHUURMAN , Paul PARREN
IPC: C07K16/28
Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
Abstract translation: 本文描述的是在第一和第二多肽链中的至少一个中包含氨基酸取代的蛋白质。 此外，描述了与所述蛋白质相关的用途和方法。
-
公开(公告)号：US20220411529A1
公开(公告)日：2022-12-29
申请号：US17774333
申请日：2020-11-06
Applicant: GENMAB B.V.
Inventor： Rob DE JONG , Frank BEURSKENS , Gijs ZOM , Janine SCHUURMAN , Xiaoguang XUE
IPC: C07K16/28
Abstract: The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.
-
公开(公告)号：US20220332801A1
公开(公告)日：2022-10-20
申请号：US17534712
申请日：2021-11-24
Applicant: GENMAB B.V.
Inventor： Annemarie KUIPERS , Kok VAN KESSEL , Frank BEURSKENS , Rob DE JONG , Kristin STRUMANE , Janine SCHUURMAN , Paul PARREN , Jos VAN STRIJP , Suzan ROOIJAKKERS
Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
